Tapering Lexapro (escitalopram)
Join us for a 60-minute webinar led by Dr. Mark Horowitz, a leading researcher in psychiatric drug withdrawal and Scientific Co-Founder of Outro Health.
Presented by Outro Health
Join us for the next edition of Outro’s Tapering Series, this time with a focused discussion on Lexapro (escitalopram) and Celexa (citalopram)—two of the most widely prescribed SSRIs in the U.S.
While often considered "easier" to taper than other antidepressants, many patients still experience significant withdrawal symptoms. This session will explore the neuroscience, clinical considerations, and real-world strategies for discontinuing these medications safely and successfully.
Whether you're a clinician, patient, or caregiver, this session will help you better understand how to approach tapering with precision and care.
👉 Can’t make it live? Register anyway and we’ll send you the recording afterward.
🧠 What You’ll Learn
Why even “mild” SSRIs like Lexapro and Celexa can cause severe withdrawal for some patients
The role of serotonin transporter occupancy and dose-response curves in tapering success
Hyperbolic tapering protocols tailored to escitalopram and citalopram
Clinical and lifestyle factors that can support smoother discontinuation
How Outro's virtual care model supports safe, step-down tapering plans
Format
The webinar includes a 40-minute presentation followed by a 20-minute Q&A. This session is ideal for clinicians, patients, caregivers, and those curious to better understand tapering protocols and emerging deprescribing standards.
Presenters
Speaker: Dr. Mark Horowitz, MD, PhD is a clinical research fellow in psychiatry at University College London and the co-founder of Outro Health. His work has helped reshape national guidelines on antidepressant withdrawal, and he is internationally recognized for his research on hyperbolic tapering and psychiatric drug dependence.
Emma Frati is a member of the Outro Health team with lived experience of polypharmacy during her time at Columbia University. She later earned a degree in Behavioral Neuroscience with a focus on statistics and business. Emma has worked in psychedelic and wearables research, co-authored a study on automated sleep scoring published in Sleep Journal, and previously consulted in the rare disease biotech space.
About Outro
Outro is a virtual care platform for safe, evidence-based antidepressant tapering. They are currently accepting patients in several US states. Learn more by visiting the Outro website at www.outro.com